I am off to Washington DC tomorrow for the annual meeting of the American Urological Association (AUA).
Nanotechnology is set to have a major impact on drug development and new products for the diagnosis and treatment of cancer. Research from UCSF and Northwestern University published earlier this year in “Science Translational Medicine” shows this potential.
In an acquisition that highlights the importance of cancer and inflammation, Gilead Sciences today announced the acquisition of Seattle based Calistoga Pharmaceuticals for $375M.
The theme for the biotech strategy blog this week is innovation in bringing new drugs and devices to market. Innovation is the lifeblood of the biotechnology industry and what drives the acquisition of companies for their pipeline by large pharma companies.
My theme for blog posts this week has been the diagnosis and detection of Alzheimer’s Disease, a therapeutic area I was first introduced to while working as a Global Project Director at the Canadian CRO, CroMedica before it was acquired by PRA. The then CEO of CroMedica, Erich Mohr Ph.D is now Chairman and CEO of MedGenesis Therapeutix Inc. in Victoria, BC.